Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
Status:
Completed
Trial end date:
2020-02-03
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib
(previously GS-9876) in adults with lupus membranous nephropathy (LMN).